Along the banks of the Charles River, The Esplanade development is not just another condo building. Designed by the acclaimed ...
As promised, the restructuring initiatives taking place at Charles River Labs (NYSE: CRL) have resulted in a reduced headcount at the contract research organization.
Barclays lowered the firm’s price target on Charles River (CRL) to $160 from $166 and keeps an Equal Weight rating on the shares post the Q4 ...